Archives
-
AT-406 (SM-406): IAP Antagonist Evidence
2026-10-08
AT-406, also called SM-406, is a research-stage antagonist of XIAP, cIAP1, and cIAP2. Product-dossier evidence supports apoptosis-related activity in cancer models, but assay metadata, independent replication, and clinical evidence remain limited.
-
Poly(I:C) and Immune Dose-Response Logic
2026-10-07
Poly (I:C), a synthetic double-stranded RNA analog, offers a useful framework for interpreting interferon signaling and immune dose-response patterns. This article connects TLR3 biology with new evidence from porcine deltacoronavirus research while defining the limits of translating synthetic immune stimulation into infection models.
-
Drying Technologies for mRNA-LNPs: What the Review Shows
2026-10-07
Zhen et al. provide a structure-aware review of freeze-drying and emerging drying technologies for mRNA and other nucleic acid lipid nanoparticles. The paper’s main contribution is to connect nucleic acid architecture, nanoparticle composition, drying stress, and intended administration route while identifying where evidence remains formulation-specific and incomplete.
-
Firefly Luciferase mRNA: Evidence and Applications
2026-10-06
Firefly Luciferase mRNA (ARCA, 5-moUTP) is best understood as a transient bioluminescent reporter for studying delivery, translation, and biological response. This overview distinguishes supplier-described design features from peer-reviewed evidence, using a 2025 lipid nanoparticle study to assess applications, findings, limitations, and research relevance.
-
GANT61 and the GLI2–PRDX1 Ferroptosis Axis
2026-10-06
A translational analysis of how GANT61 can help interrogate GLI2-driven ferroptosis resistance, while separating mechanistic promise from evidence limitations in bladder cancer research.
-
EDC.HCl Product Overview and Evidence Limits
2026-10-05
EDC.HCl, also known as 3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride or CAS 25952-53-8, is listed by APExBIO as a water-soluble carbodiimide reagent for conceptual carboxyl-group activation and amide bond formation. No matched research paper or independent performance evidence was provided.
-
LDH Cytotoxicity Assay Kit in Pyroptosis Research
2026-10-05
A source-grounded overview of how LDH release can support cell cytotoxicity measurement in RNA-responsive pyroptosis research, with emphasis on evidence strength, interpretation limits, and applicability to cancer and translational studies.
-
740 Y-P in PI3K/AKT Signaling Research
2026-10-04
A source-grounded overview of 740 Y-P as a research probe for PI 3-kinase signaling, including its conceptual relevance to vesicular trafficking, apoptosis assays, cancer research, and neuronal cell survival. The available evidence is compared with a 2025 capsaicin study in oxidative-stressed bone marrow stromal cells, with clear boundaries around what can and cannot be inferred.
-
Merbromin Inhibits SARS-CoV-2 3CLpro
2026-10-03
A 2022 study identified merbromin as a selective biochemical inhibitor of the SARS-CoV-2 3CLpro main protease after screening approximately 6,000 compounds. Kinetic, binding, and docking evidence supported a mixed-type inhibition model and suggested two interaction sites, while comparison with Proteinase K, trypsin, and papain indicated protease selectivity.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-10-02
A 2022 Journal of Molecular Medicine study identified ziprasidone as a noncompetitive inhibitor of GOT1, linking enzyme inhibition to glutamine-metabolism disruption, redox imbalance, and reduced pancreatic ductal adenocarcinoma growth. Its integrated biochemical, cellular, genetic, metabolic, and xenograft evidence supports GOT1 as a therapeutic hypothesis while leaving questions about selectivity, mechanism, and clinical translation.
-
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-10-01
Cy3 Goat Anti-Rabbit IgG (H+L) Antibody provides fluorescent detection of rabbit IgG primary antibodies in immunofluorescence, IHC, ICC, and flow cytometry workflows. It is intended for research use only, and its suitability should be validated for each sample type, imaging system, and multiplex panel rather than assumed for diagnostic, medical, or untested live-cell applications.
-
Esculin Mechanisms in Renal Cell Carcinoma
2026-10-01
This 2024 Biomolecules study combines network pharmacology, molecular docking, and cell-based validation to investigate how esculin affects renal cell carcinoma. The results connect reduced proliferation and migration with apoptosis, GAPDH-related signaling, and suppression of the PI3K/Akt pathway, while also illustrating how EdU-based DNA synthesis measurement can strengthen anticancer mechanism studies.
-
Pravastatin Sodium in Transporter-Aware Research
2026-09-30
Pravastatin sodium is a selective HMG-CoA reductase inhibitor with applications spanning cholesterol biosynthesis inhibition and cardiovascular disease prevention. This article develops a transporter-aware framework for connecting pravastatin pharmacology with hepatocyte viability, botanical-drug interaction screening, and carefully bounded translational research.
-
Veratridine: From Channel Opening to Cell Injury
2026-09-30
Veratridine is a voltage-gated sodium channel opener that links membrane excitability to downstream neuronal injury. This guide explains how to design and interpret sodium channel dynamics research, excitotoxicity studies, and blocker-screening assays without confusing upstream activation with final cell death.
-
GLI2, WNT, and Prostaglandins in Immunotherapy Resistance
2026-09-29
The reference study identifies GLI2 as a mechanistic link between mesenchymal transformation and an immunosuppressive tumor microenvironment, acting through coordinated WNT ligand production and prostaglandin signaling. Its perturbation and immunotherapy experiments suggest that GLI2-associated pathways may guide rational combinations for overcoming anti-PD-1 resistance, while also highlighting the need for context-specific validation.